RSS | Login | Register

COMBIVIR

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare COMBIVIR to:

Generic Name for COMBIVIR

Lamivudine 150mg, zidovudine 300mg; tabs.

Legal Classification:

Pharmacological Class for COMBIVIR

Nucleoside analogues (reverse transcriptase inhibitors).

Manufacturer of COMBIVIR

GlaxoSmithKline Pharmaceuticals

Indications for COMBIVIR

HIV infection.

Adult dose for COMBIVIR

1 tab twice daily. Hepatic or renal dysfunction (CrCl <50mL/min): not recommended.

Children's dosing for COMBIVIR

Not recommended.

Precautions for COMBIVIR

Bone marrow depression. Anemia. Not for use with other lamivudine or zidovudine products. Hepatitis B (monitor for post-treatment exacerbation). Decompensated liver disease or risk factors for liver disease. Suspend if lactic acidosis or hepatotoxicity (e.g., hepatomegaly, steatosis) occurs. Women, obesity, prolonged nucleoside exposure: increased risk of toxicity. Monitor blood counts. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for COMBIVIR

See literature. Avoid concomitant other forms of zalcitabine, stavudine, doxorubicin, ribavirin. Bone marrow suppression increased by ganciclovir, interferon-alpha, cytotoxic drugs. TMP/SMX, atovaquone, fluconazole, methadone, probenecid, valproic acid, possibly others may affect lamivudine or zidovudine blood levels (clinical significance unknown); monitor. Triple therapy (once daily regimen) with abacavir + tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see literature). Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.

Adverse Reactions for COMBIVIR

Headache, GI upset, malaise, fatigue, nasal symptoms, cough, musculoskeletal pain, neuropathy, insomnia, fever/chills, dizziness, depression, rash, myalgia, arthralgia, lab abnormalities (neutropenia, severe anemia, thrombocytopenia, elevated ALT/AST, bilirubin or amylase), hyperglycemia, seizures, lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, myopathy; pancreatitis (rare).

How is COMBIVIR supplied?

Tabs—60

Related Disease:

HIV~antivirals

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).